Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848328 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00848328 is a Phase 2 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 30 participants.
The verdict
NCT00848328, a Phase 2 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with rituximab works in treating patients with follicular or small lymphocytic non-Hodgkin lymphoma that has relapsed or not responded to treatment.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-08-25 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848328
The ClinicalTrials.gov registry entry for NCT00848328 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT00848328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00848328 about?
NCT00848328 is a clinical study titled "Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma". RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find can...
What is the current status of trial NCT00848328?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-08-25. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT00848328?
The interventions under investigation include: Lenalidomide (DRUG), Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00848328?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.